Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0LNARP
ADC Name	MEDI-0641
Synonyms	MEDI0641; MEDI 0641; 5T4-PBD Click to Show/Hide
Organization	MedImmune LLC; AstraZeneca PLC
Drug Status	Clinical candidate
Indication	In total 1 Indication(s) Solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Clinical candidate
Drug-to-Antibody Ratio	2
Structure
	3D MOL	2D MOL
Antibody Name	5T4_0108		Antibody Info
Antigen Name	Trophoblast glycoprotein (TPBG)		Antigen Info
Payload Name	5T4-PBD		Payload Info
Therapeutic Target	Human Deoxyribonucleic acid (hDNA)		Target Info
Linker Name	Mal-PEG8-Val-Ala-PABC		Linker Info

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 91.3	%	MDA-MB-361 cells	Breast adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 91.30% (Day 49)	Positive 5T4 expression (5T4+++/++)
Method Description	A single dose of 5T4-PBD was administrated at 0.1 and 0.3 mg/kg intravenously into nude mice.
In Vivo Model	MDA-MB-361 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

References

Ref 1	Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition. Mol Cancer Ther. 2019 Jan;18(1):89-99. doi: 10.1158/1535-7163.MCT-18-0314. Epub 2018 Oct 23.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.